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school 4 years after implantation. This prospective economic analysis adopted 
the health care payer’s perspective and took into account direct medical,  
direct non-medical and indirect costs RESULTS: Two hundred and three 
implanted children were included in the study and followed during four years. 
The rate of school children implanted later (i.e. after 2 years) goes from 71,4% to 
95,3% four year after implantation and goes from 28,6% to 87,5% for children 
implanted earlier (i.e. before 2 years). If children are implanted earlier (i.e. < 2 
years), they are more likely to integrate ordinary classroom four years after 
implantation (69.0%) than if children were implanted later (46,9%). The mean 
total costs over one year period were €34,703 (+/- 5,231). The preoperative, 
implantation and one year follow-up mean costs were €1,304 (+/- 1,014), €24,285 
(+/- 1,150) and €9,115 (+/-4,694) respectively. Ambulatory care was the costs 
driver in preoperative and one year follow up costs (42,0% and 66,6% 
respectively), while in implantation costs the driver was implant cost (90,0%). 
The cost of the next three year follow-up is being processed CONCLUSIONS: CI is 
an expensive medical treatment but they have a positive impact on children 
education.  
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OBJECTIVES: The purpose of this study was to describe the use of biologics in the 
treatment of psoriasis, in a real life Canadian setting. METHODS: A retrospective 
study of the Quebec provincial drug reimbursement program (RAMQ) was 
conducted using a random sample of patients who had received at least one 
diagnosis of psoriasis (ICD-9: 6961/6968/6969) and had used at least one biologic 
in the period from January 1, 2001 to August 31, 2011. Agents included in the 
study were adalimumab, etanercept, infliximab, abatacept, anakinra, efalizumab, 
golimumab, rituximab, tocilizumab and ustekinumab. The use of biologics was 
analyzed in terms of patient characteristics, treatment patterns and health care 
resource utilization. RESULTS: A total of 1382 patients who used at least one 
biologic were included in the study. The average age was 45,8 years (SD=15,0) 
and the proportion of men was slightly higher (53,5%). Most patients had other 
concomitant inflammatory diseases (80,8%), such as rheumatoid arthritis (48.6%), 
psoriatic arthritis (44.9%), and Crohn’s disease (15.0%). During the course of the 
study period, most patients used only one biologic (80.3%). Out of the 34,320 
scripts for a biologic, 16,421 were for etanercept (47.9%), 8,868 for adalimumab 
(25.8%) and 7174 for infliximab (20.9%). Average annual cost for biologics in 
psoriasis was $19,026 and was slightly higher in the first year of treatment. Costs 
per patient of health care resource utilization in the year following the initiation 
of a biologic were $CAD486 lower than during the one year period preceding the 
biologic initiation; 45% of this reduction was associated with outpatient visits 
and 23% with hospitalizations. CONCLUSIONS: Psoriasis is associated with many 
other inflammatory conditions. Biologics use for the treatment of psoriasis has 
significantly increased over time. Although this is associated with higher 
medication costs, the initiation of a biologic is associated with a reduction of 
other medical costs.  
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OBJECTIVES: Itchy and dry skin, symptoms of pruritus, are commonly reported 
by patients with end-stage renal disease (ESRD) and may impact health 
outcomes. However, the economic burden to dialysis facilities is poorly 
understood. This retrospective cohort study measured dialysis-related costs in 
patients reporting itchiness/dryness at a large dialysis organization (LDO). 
METHODS: Adult patients (≥ 18 years old) were identified in the LDO database if 
they responded to the Kidney Disease Quality of Life (KDQOL) survey 
administered between December 1, 2008 and June 30, 2012, which included 
questions about itchy/dry skin. Medicare patients were included if they 
answered a survey ≥ 3 months after dialysis initiation. Costs of medications, 
laboratories, and missed sessions were measured over a 6-month follow-up 
period. Patients were censored for death, transplant, change in treatment 
modality, discontinued treatment, or loss of observation. Mean utilization for 
medication and laboratory costs was determined by unit prices published in RED 
BOOK and physician fee and coding guide. Costs of missed sessions were derived 
by the standard 2012 Medicare composite reimbursement rate for in-center 
dialysis. Cost differences were determined by covariate adjusted generalized 
linear mixed models. RESULTS: Over the 6-month period, in unadjusted models 
(n = 38,815) increasing trends in total costs were observed with increasing 
severity of itchiness ($507, $803, $1,520, and $2,238) and dryness ($542, $840 
$1,610, and $2,729) compared to no itchiness/dryness. The adjusted model 
demonstrated similar trends, yet attenuated differences. A subgroup analysis 
comparing combined severe itchiness and dryness versus neither itchiness nor 
dryness showed a mean estimate of $2348 increased costs. All results were 
statistically significant (p < 0.0001). Drivers of overall dialysis costs were 
increased utilization of erythropoiesis-stimulating agents and missed sessions. 
CONCLUSIONS: ESRD patients with pruritus symptoms impose higher costs to 
dialysis facilities. Pruritus symptom relief may be an important target for 
therapeutic intervention.  
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OBJECTIVES: Anti-VEGF therapy with ranibizumab (RBZ) dosed monthly improves 
visual acuity over time in patients with neovascular (“wet”) age-related macular 
degeneration (wAMD). In two identical phase 3 trials, IAI dosed every 2 months, 
following 3 initial monthly doses demonstrated clinically equivalent efficacy and a 
similar safety profile to RBZ0.5mg dosed monthly (RBZQ4). We assessed U.S. cost 
effectiveness of IAI 2Q8 compared with RBZ Q4 in treating wAMD. METHODS: A 
Markov model was developed to characterize treatment with IAI 2Q8 and RBZ Q4 
over two years. Patients move among health states based on visual acuity in the 
better-seeing eye. The model assumed patients discontinue treatment when vision 
drops below 20/400; ten percent were assumed to be treated in both eyes. The 
model calculated direct medical costs (drug, administration, monitoring, vision 
impairment and adverse events) and quality adjusted life-years (QALYs). Model 
parameters were estimated from clinical trial data, published literature, or expert 
opinion. Cost-effectiveness was reported through incremental cost-effectiveness 
ratios (ICERs) for a 2-year horizon. Costs and outcomes were discounted 3% per 
year. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: 
Treatment with IAI 2Q8 cost $30,700 over two years, compared with $54,300 for RBZ 
Q4. Treatment cost was the largest cost component, comprising 78% and 85% of 
total costs of the IAI and RBZ regimens, respectively. Both regimens resulted in 
similar QALY gains (1.124 for IAI, 1.125 for RBZ). Compared with IAI, RBZ cost nearly 
$26 million per QALY gained. The model was most sensitive to unit drug cost and 
utility weights. IAI was dominant in 41% of PSA iterations. CONCLUSIONS: In 
treating wAMD, IAI 2mg dosed every 2 months, following 3 initial monthly doses is 
less expensive than monthly RBZ. Both demonstrate similar efficacy. Of the two, IAI 
is the cost-effective alternative at conventional willingness to pay thresholds.  
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OBJECTIVES: To determine the comparative cost-effectiveness of three 
commercially available cellular engineered skin substitutes used in the 
treatment of venous leg ulcers (VLU). METHODS: A Markov simulation model 
was developed to compare the one year direct costs and outcomes of a porcine 
small intestinal submucosa (SIS) wound matrix to fibroblast-derived (FSS) and 
fibroblast/keratinocyte-derived (FKSS) cellular and/or tissue-derived products 
(CTDP) used in the treatment of chronic VLUs. The model used three health 
states: a chronic ulcer, a healed ulcer and death. To predict clinical and 
economic outcomes a systematic literature search was conducted to identify 1) 
comparative chronic VLU clinical trials that reported healing/recurrence 
outcomes for the three skin substitutes, and 2) economic studies reporting VLU 
treatments and resource utilization. The effectiveness of the products was 
assumed equal to that reported in four clinical trials identified in the literature. 
Ulcer-free weeks were used as the measure of clinical effectiveness. Direct costs 
of treatment were derived from Medicare-allowable costs and economic studies 
identified in the literature which included costs associated with hospitalization, 
home health care, ambulatory clinic visits, CTDP products, drugs, compression 
stockings and other resources associated with VLU care. The payer perspective 
was taken in the analysis and sensitivity analyses were performed to assess 
model uncertainty. RESULTS: SIS was the economically dominant therapy 
compared to FKSS and FSS with a comparative effectiveness ratio of $215 per 
ulcer-free week versus $367 and $409, respectively. Relative to SIS, the 
incremental cost-effectiveness ratio (ICER) for FKSS was $1609 while the ICER for 
FSS was $1132. SIS remained the least costly alternative per ulcer-free week 
across all sensitivity analyses. CONCLUSIONS: When cellular and/or tissue-
derived products are needed for chronic VLU therapy our results indicate that SIS 
is the most cost-effective choice between the three commercially available 
alternatives analyzed.  
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OBJECTIVES: This pharmacoeconomic study evaluates the cost-effectiveness of 
OZURDEX™ (dexamethasone intravitreal implant) compared to observation 
(primary intervention at the time of model development) in management of 
patients with ME following CRVO, from a Canadian public payer and societal 
perspective. METHODS: A Markov model was developed to estimate lifetime 
outcomes and costs for patients with ME and vision loss following CRVO, 
receiving either OZURDEXTM implant or observation. The model consists of six 
heath states based on Best Corrected Visual Acuity (BCVA) and one absorbing 
(Death) state. The model was developed using GENEVA trial results with a 
systematic review for extrapolation of clinical data beyond the trial period. The 
model incorporated direct medical costs of managing patients with CRVO, 
treatment, drug related adverse events and vision loss; a societal perspective 
was examined as well. Utilities were derived from the published literature based 
